Nev Black Posted November 8, 2019 Share Posted November 8, 2019 Imugene is a company listed on the Australian Stock Exchange. (This is not a recommendation to buy shares in this company) CF33 is an Oncolytic Virotherapy which will be used in a Phase 1 Trial, in Australia, starting next year. CF33 will be trailed on a number of cancers. Unfortunately, Prostate Cancer was not on the list. 04/11/2019 Imugene Receives $4.13 million R&D Tax Incentive https://static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t/5dbfcc1869d48f23f8e0a4bd/1572850714901/Imugene+Receives+%244.13+million+R%26D+Tax+Incentive.pdf 21/10/2019 CF33 Oncolytic Virus Clinical Trial Program Update https://static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t/5dac7a22fe152f3a7a9ce236/1571584547049/CF33+Clinical+Development+Plan.pdf (The announcements below are publicly available on the Australian Stock Exchange Announcements page) Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.